Adult-onset diabetes is a disease characterized by high blood glucose levels and is one of the leading causes of cardiovascular disease, blindness, end-stage renal failure, and hospitalization. Recent studies support the idea that bacteria found in the gut may play an important role in the development and progression of diabetes. Changes in the gut bacterial environment can affect blood glucose and blood lipids. A increasing number of recent studies have shown that probiotics can alter the gut bacterial environment and reduce blood glucose and blood lipids. The aim of this study is to investigate the effects of probiotics, administered in addition to your current medications, on blood glucose and blood lipids.
Participants aged 35-65 years diagnosed with T2DM were allocated sequentially according to order of presentation to either probiotic group (n=39) or control group (n=38). The intervention group received a multi-strain probiotic supplement containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium lactis and Lactobacillus paracasei, twice daily for 12 weeks, while the control group continued standard care. This study evaluated anthropometric measurements, eating attitudes, dietary frequency, quality of life, and physical activity. Biochemical analyses included glycemic control, lipid profiles, inflammation markers (high-sensitivity C-Reactive Protein, Ceruloplasmin), and oxidative stress markers (Malondialdehyde, Glutathione).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
77
Patients in the intervention group were given a probiotic supplement containing Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium lactis and Lactobacillus paracasei, each containing 1.25 billion live microorganisms, without vitamins and minerals, twice a day in addition to their current treatment for 12 weeks (Probiotic group). Patients in the control group were not given any additional treatment and were allowed to continue their routine antidiabetic treatment for 12 weeks (Control group).
Ege University Faculty of Medicine
Izmir, Turkey (Türkiye)
Efficacy of probiotics on inflammatory markers
hs-CRP
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on inflammatory markers
Ceruloplasmin
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on antioxydant systems
Glutathion
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on antioxydant systems
malondialdehyde
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on glucose metabolism
Postprandial Blood Glucose
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on glucose metabolism
Fasting Blood Glucose
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on glucose metabolism
HbA1c
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on lipid metabolism
LDL Cholesterol
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on lipid metabolism
HDL Cholesterol
Time frame: From enrollment to the end of treatment at 12 weeks
Efficacy of probiotics on lipid metabolism
Triglyceride
Time frame: From enrollment to the end of treatment at 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.